Abstracts Archive - Page 1646 of 2607 - ACR Meeting Abstracts

Abstract Number: 698 • 2016 ACR/ARHP Annual Meeting
Performance of Modified Minimal Disease Activity (MDA) in Patients with Peripheral Spondyloarthritis
Laura C. Coates¹, Sonya Abraham², William Tillett³, Philip J Mease⁴, Sofia Ramiro⁵, Yinglin Xia⁶, Xin Wang⁷, Aileen L. Pangan⁷ and In-Ho Song⁷, ¹University of Leeds, Leeds, United Kingdom, ²NIHR/Wellcome CRF, Imperial College Healthcare NHS Trust, London, United Kingdom, ³Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶University of Illinois at Chicago, Chicago, IL, ⁷AbbVie Inc., North Chicago, IL
Background/Purpose: Due to lack of validated outcome measures in non-psoriatic peripheral spondyloarthritis (pSpA), recent studies in this patient (pt) population have used varying endpoints [1].…
Abstract Number: 699 • 2016 ACR/ARHP Annual Meeting
In Contrast to Men, Women with Nonradiographic Axial Spondyloarthritis Have Lower Response Rates to TNF Inhibitors Than Women with Ankylosing Spondylitis
Adrian Ciurea¹, Monika Hebeisen², Ulrich Weber^3,4, Giorgio Tamborrini⁵, Raphael Micheroli¹, Lukas Wildi¹, Pascal Zufferey⁶, Michael J. Nissen⁷, Peter M. Villiger⁸, Juerg Bernhard⁹, Désirée van der Heijde¹⁰, RBM Landewé^11,12, Almut Scherer² and Pascale Exer¹³, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²SCQM Foundation, Zurich, Switzerland, ³Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, ⁴Department of Research, King Christian 10th Hospital for Rheumatic Diseases, Graasten, Denmark, ⁵Department of Rheumatology and Musculoskeletal Ultrasound, Bethesda Hospital Basel, Basel, Switzerland, ⁶Rheumatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ⁷Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁸Rheumatology, Clinical immunology & Alllergology, University Hospital Bern, Bern, Switzerland, ⁹Rheumatology Center, Buergerspital, Solothurn, Switzerland, ¹⁰Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ¹¹Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ¹²Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands, ¹³Private rheumatology practice, Basel, Switzerland
Background/Purpose: Response to tumor necrosis factor inhibition (TNFi) has been shown to be similar in nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) in patients…
Abstract Number: 700 • 2016 ACR/ARHP Annual Meeting
Incidence of Inflammatory Bowel Disease Events in Adalimumab (HUMIRA) Clinical Trials Across Indications
Jeffrey R. Curtis¹, Dirk Elewaut², Su Chen³, Maja Hojnik⁴, Navit Naveh⁵ and Jaclyn K. Anderson³, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²VIB Inflammation Research Center, University of Ghent, Ghent, Belgium, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie, Ljubljana, Slovenia, ⁵AbbVie, Hod HaSharon, Israel
Background/Purpose: Adalimumab (ADA) is approved for treatment of Crohn’s disease (CD) and ulcerative colitis (UC); therefore, it is postulated that new onset or flare of…
Abstract Number: 701 • 2016 ACR/ARHP Annual Meeting
In Patients with Ankylosing Spondylitis Treated with Adalimumab, Combination Therapy with DMARD, Increase the Serum Level of Adalimumab and Decrease Immunogenicity
José Rosas¹, Francisca Llinares-Tello², José Miguel Senabre-Gallego¹, Mariana Marco-Mingot³, Ana Pons¹, Xavier Barber⁴, Gregorio Santos-Soler¹, Esteban Salas-Heredia¹, Catalina Cano¹, Juan Molina³, Marina Sanchís⁴, Mario García-Carrasco⁵ and AIRE-MB Group, ¹Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ²Laboratory, Hospital Marina Baixa, Villajoyosa, Spain, ³Laboratory, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ⁴CIO, Universidad Miguel Hernández, Elche, Spain, ⁵Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: In patients with rheumatoid arthritis, methotrexate (MTX), improves the clinical efficacy of anti-TNF (TNFi), among other reasons, for reducing the immunogenicity. However, there are…
Abstract Number: 702 • 2016 ACR/ARHP Annual Meeting
Treatment with Golimumab or Infliximab Reduces Health Resource Utilization and Increases Work Productivity in Patients with Ankylosing Spondylitis in a Large, Prospective Real-Life Cohort
Pascal Claudepierre¹, Filip van Den Bosch², Piercarlo Sarzi-Puttini³, Shiva Sajjan⁴, N Vastesaeger⁵, Marinella Govoni⁶ and Sumesh Kachroo⁷, ¹Hôpital Henri Mondor, Créteil, France, ²Rheumatology, Ghent University Hospital, Ghent, Belgium, ³Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, ⁴Merck & Co., Inc., Kenilworth, NJ, ⁵Merck Sharp & Dohme, Belgium, Brussels, Belgium, ⁶Via Tasso 14, Merck Sharp & Dohme, Italy, Cento, Italy, ⁷CORE, Merck & Co., Inc., Kenilworth, NJ
Background/Purpose: We evaluated the effect of the anti-tumor necrosis factor (TNF) agents, golimumab (GLM) and infliximab (IFX), on healthcare resource utilization (HCRU) and work productivity…
Abstract Number: 703 • 2016 ACR/ARHP Annual Meeting
Performance of a New Spinal Mobility Index for Patients with Axial Spondyloarthritis
Graciela Betancur¹, Fernando Andres Sommerfleck², Ana Lizarraga¹, Natalia Zamora³, Maria Celeste Orozco³, Susana Gagliardi⁴, Emilce Schneeberger⁵ and Gustavo Citera⁵, ¹Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Rheumatology, Instituto de Rehabilitación Psicofísica, CABA, Argentina, ⁵Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: ASAS recommends using BASMI for evaluation of axial mobility in patients with Axial Spondyloarthritis (axSpA). The EDASMI (Edmonton Ankylosing Spondylitis Metrology Index) is another…
Abstract Number: 704 • 2016 ACR/ARHP Annual Meeting
Does Change in Disease Activity over One Year Result in Change in Health-Related Quality of Life in Early Axial Spondyloarthritis Patients?
Miranda van Lunteren¹, Zineb Ez-Zaitouni¹, Pauline Bakker¹, Hanne Dagfinrud², Robert Landewé³, Maikel van Oosterhout⁴, Roberta Ramonda⁵, Floris van Gaalen¹ and Désirée van der Heijde¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Academic Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, Groene Hart Ziekenhuis, Gouda, Netherlands, ⁵Rheumatology Unit, University of Padova, Padova, Italy
Background/Purpose: In axial Spondyloarthritis (axSpA), treatment is targeted at reducing disease activity with the aim of improving the health-related quality of life (HRQoL). Therefore, it…
Abstract Number: 705 • 2016 ACR/ARHP Annual Meeting
Is a Positive Family History of Spondyloarthritis of Value in Patients with Chronic Back Pain? Results from Two Large Early Back Pain Cohorts
Zineb Ez-Zaitouni¹, Laure Gossec², Inger Jorid Berg³, Robert Landewé⁴, Maikel van Oosterhout⁵, Mariagrazia Lorenzin⁶, Maxime Dougados⁷, Désirée van der Heijde⁸ and Floris van Gaalen¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Paris 06 University and AP-HP, Hôpital Pitié Salpêtrière, Paris, France, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Amsterdam Medical Center, Amsterdam, Netherlands, ⁵Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁶Rheumatology Unit, Department of Medicine DIMED, Rheumatology Unit,University of Padova, Padova, Italy, ⁷Paris-Descartes University, Paris, France, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: To assess whether presence of spondyloarthritis (SpA) manifestations in first- and second-degree relatives of patients with chronic back pain (CBP) is associated with higher…
Abstract Number: 706 • 2016 ACR/ARHP Annual Meeting
Performance of the ASAS Classification Criteria for Axial and Peripheral Spondyloarthritis – a Systematic Literature Review and Meta-Analysis
Alexandre Sepriano¹, Roxana Rubio¹, Sofia Ramiro¹, Robert Landewé² and Désirée van der Heijde³, ¹Leiden University Medical Center, Leiden, Netherlands, ²Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) has developed and validated classification criteria for axial spondyloarthritis (axSpA) and peripheral SpA (pSpA). Following their release,…
Abstract Number: 707 • 2016 ACR/ARHP Annual Meeting
Anti-TNF Drugs Are Not Associated with Increasead Risk of Hzv Infections in Patients with Spondyloarthritis (SpA): Results from the GISEA Registry
Fabiola Atzeni¹, Marco Sebastiani², Valentina Panetta³, Fausto Salaffi⁴, Florenzo Iannone⁵, Elisa Gremese⁶, Antonio Carletto⁷, Antonio Marchesoni⁸, Roberto Gorla⁹, Marcello Govoni¹⁰, Rosario Foti¹¹, Ennio G. Favalli¹², Roberta Ramonda¹³, Pier Carlo Sarzi-Puttini¹⁴, Giovanni Lapadula¹⁵ and Gianfranco Ferraccioli¹⁶, ¹Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, ²SC Reumatologia, Dipartimento di Medicine, Medicina d’Urgenza e Specialità Mediche, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy, ³L'altrastatistica -Consultancy & Training- Biostatistics office., Rome, Italy, ⁴Rheumatology Department, Polytechnic University of Marche, C. Urbani Hospital, Jesi,, Ancona, Italy, ⁵Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, General Hospital, Bari, Italy, ⁶Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ⁷Rheumatology Unit, University of Verona, Verona, Italy, ⁸Department of Rheumatology, Gaetano Pini Institute, Milan, Italy, ⁹Rheumatology and Immunology Unit, Spedali Civili di Brescia, Brescia, Italy, ¹⁰Medical Sciences, UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, ¹¹Rheumatology Unit, Vittorio-Emanuele University Hospital of Catania, Catania, Italy, ¹²Department and Chair of Rheumatology, University of Milan, Gaetano Pini Institute, Milan, Italy, ¹³Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy, ¹⁴Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ¹⁵Rheumatology Unit, University of Bari, Bari, Italy, ¹⁶Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Herpes zoster virus (HZV) reactivation disproportionately affects patients with systemic rheumatic diseases and it is commonly described in short- and long-term use of anti-Tumor…
Abstract Number: 708 • 2016 ACR/ARHP Annual Meeting
Development of Spondyloarthritis-Features in Patients with Chronic Back Pain over a One-Year Course: Data from the Spondyloarthritis Caught Early (SPACE)-Cohort
Zineb Ez-Zaitouni¹, Miranda van Lunteren¹, Pauline Bakker¹, Inger Jorid Berg², Robert Landewé³, Maikel van Oosterhout⁴, Augusta Ortolan⁵, Désirée van der Heijde¹ and Floris van Gaalen¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁵Rheumatology Unit, Department of Medicine DIMED, Rheumatology Unit,University of Padova, Padova, Italy
Background/Purpose: Little is known on the development of spondyloarthritis (SpA)-features over time in patients with recent onset chronic back pain (CBP). The aim was to…
Abstract Number: 709 • 2016 ACR/ARHP Annual Meeting
Development of a Novel Medication Adherence Prediction Model for Patients with Ankylosing Spondylitis Based on Results from a Global Clinical Study
Philip J Mease¹, Josef S. Smolen², Dafna D Gladman³, Joachim Sieper⁴, John Weinman⁵, Julia Sommer⁶, Pascal Nurwakagari⁷ and Maja Hojnik⁸, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Medical University of Vienna, Vienna, Austria, ³University of Toronto, Toronto, ON, Canada, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵King's College, London, United Kingdom, ⁶GKM Gesellschaft für Therapieforschung mbH, Munich, Germany, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸AbbVie, Ljubljana, Slovenia
Background/Purpose: Adherence to systemic therapies, such as tumor necrosis factor inhibitors (TNFi’s), is affected by various factors and may be critical for optimal disease outcomes…
Abstract Number: 710 • 2016 ACR/ARHP Annual Meeting
Patient-Reported Quality of Life in Patients with Baseline Objective Signs of Inflammation and Active Nonradiographic Axial Spondyloarthritis Treated with Golimumab: Results of the Open-Label Extension of a Randomized, Double-Blind Study
Walter Maksymowych¹, Maxime Dougados², Joachim Sieper³, Jürgen Braun⁴, G Bergman⁵, Sean P. Curtis⁶, Anjela Tzontcheva⁶, George Philip⁶, Susan Huyck⁶ and Désirée van der Heijde⁷, ¹Medicine, University of Alberta,, Edmonton, AB, Canada, ²Paris-Descartes University, Paris, France, ³Rheumatology Department, Charité – University Medicine Berlin, Berlin, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Merck & Co., Inc., Whitehouse Station, NJ, ⁶Merck & Co., Inc., Kenilworth, NJ, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In an open-label extension (OLE) of a 16-week, randomized, double blind (DB), placebo (PBO)-controlled, phase 3 study (GO-AHEAD; NCT1453725) in patients with nonradiographic axial…
Abstract Number: 711 • 2016 ACR/ARHP Annual Meeting
The Diagnostic Value of the Symptom of Inflammatory Back Pain in the Rheumatology Setting
Denis Poddubnyy¹, Inge Spiller¹, Joachim Listing², Jürgen Braun³, Joachim Sieper¹ and Martin Rudwaleit⁴, ¹Charité Medical University, Berlin, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany
Background/Purpose: Inflammatory back pain (IBP) as a symptom has been shown to perform effectively for selecting patients in primary care / orthopaedic settings for referral…
Abstract Number: 712 • 2016 ACR/ARHP Annual Meeting
Efficacy of Golimumab for Nonradiographic Axial Spondyloarthritis (nr-axSpA): Subgroup Analysis By Baseline MRI and C-Reactive Protein Status
Joachim Sieper¹, Désirée van der Heijde², Walter Maksymowych³, Jürgen Braun⁴, G Bergman⁵, Sean P. Curtis⁶, Anjela Tzontcheva⁶, George Philip⁶, Susan Huyck⁶ and Maxime Dougados⁷, ¹Rheumatology Department, Charité – University Medicine Berlin, Berlin, Germany, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Medicine, University of Alberta,, Edmonton, AB, Canada, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Merck & Co., Inc., Whitehouse Station, NJ, ⁶Merck & Co., Inc., Kenilworth, NJ, ⁷Paris-Descartes University, Paris, France
Background/Purpose: Efficacy of golimumab (GLM) for nr-axSpA was demonstrated in a randomized, double-blind (DB), placebo (PBO)-controlled, phase 3 study (GO-AHEAD; NCT01453725).1 In a subgroup analysis,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].